Zoledronic acid can not treat bone fiber dysplasia , although there are some studies using zoledronic acid to treat bone fiber dysplasia, but there is a lack of sufficient evidence. Bone fiber dysplasia requires standardized bisphosphonates, calcium and other medications and surgical treatment, please consult a doctor in time for standardized treatment. Zoledronic acid belongs to nitrogen-containing bisphosphonate compounds, which have a high affinity for mineralized bone, and can act selectively on bone, inhibiting bone resorption by inhibiting osteoclasts. Therefore, the indications for zoledronic acid are osteoporosis and Paget’s disease. Common adverse effects of zoledronic acid include fever, myalgia, arthralgia, and headache. Osteofibrous dysarchitecture, also called osteofibrous dysplasia, is a bone disease characterized by degeneration of bone fibers, which is associated with a relatively high risk of secondary pathological fractures. It can be treated with a combination of bisphosphonates, calcium, and vitamin D. Symptomatic treatment may also be indicated. For pathologic fractures of the vertebral body, surgical procedures such as decompression and fusion with internal fixation and minimally invasive treatment can be used to remove or resect the lesion, and postoperative support can be used to maintain spinal stability. If the diagnosis of poor bone fiber structure, should go to the hospital in time, under the guidance of the doctor standardized treatment.